REG - Theracryf PLC - Notice of Results and Ox-1 presentation

TheracryfAnnouncement

23/05/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250523:nRSW9523Ja&default-theme=true

RNS Number : 9523J  Theracryf PLC  23 May 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Notice of Full Year results and Ox-1 presentation

 

Alderley Park, 23 May 2025 - TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on neuropsychiatry and oncology, announces
that the Company's full year results for the year to 31 March 2025 will be
released on Tuesday, 3 June 2025. A live presentation of the results will be
provided at 1pm BST that day via Investor Meet Company
(https://www.investormeetcompany.com/theracryf-plc/register-investor) by Dr
Huw Jones, CEO, Toni Hänninen, CFO and Dr Alastair Smith, Chair.

 

Post-results, on 11 June 2025, the Company will be hosting a separate webinar
for investors at 11.30am BST, to provide an in-depth look at the Ox-1
addiction programme. The session will be led by TheraCryf's CBO, Dr Helen
Kuhlman, together with neuroscientist and consultant to the Company, Dr Fraser
Murray. Access to the session will also be via the Investor Meet Company
platform.

 

Both presentations will be open to all existing and potential shareholders.
Questions can be submitted up to 24 hours prior to either event via the
Investor Meet Company dashboard or during the live presentations. Investors
who already follow TheraCryf plc on the Investor Meet Company platform will
automatically be invited. New registrants can sign up to Investor Meet Company
HERE (https://www.investormeetcompany.com/theracryf-plc/register-investor) .

 

-Ends-

Enquiries

 TheraCryf plc                                          +44 (0)1625 315 090

 Dr Huw Jones, CEO                                      enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Turner Pope Investments (Joint Broker)                 +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Cavendish Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

 Vigo Consulting                                        +44 (0)20 7390 0231

 Rozi Morris                                            theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma**
and neurodevelopmental disorders [**orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORPKNBKABKKAPB